CONTENTS

Analysis of Motor Function in Patients with Duchenne Muscular Dystrophy

  • ZHANG Hao ,
  • ZHOU Ning ,
  • WU Shi-wen
Expand
  • 1. Department of Neurology, General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China;
    2. Department of Neurology, the First Hospital of Beijing Fangshan District, Beijing 102400, China

Received date: 2017-10-26

  Revised date: 2017-12-07

  Online published: 2018-03-02

Cite this article

ZHANG Hao , ZHOU Ning , WU Shi-wen . Analysis of Motor Function in Patients with Duchenne Muscular Dystrophy[J]. Chinese Journal of Rehabilitation Theory and Practice, 2018 , 24(2) : 214 -218 . DOI: 10.3969/j.issn.1006-9771.2018.02.018

References

[1] Mah JK, Korngut L, Fiest KM, et al.A systematic review and meta-analysis on the epidemiology of the muscular dystrophies[J]. Can J Neurol Sci, 2016, 43(1): 163-177.
[2] Mendell JR, Shilling C, Leslie ND, et al.Evidence-based path to newborn screening for Duchenne muscular dystrophy[J]. Ann Neurol, 2012, 71(3): 304-313.
[3] McDonald CM. Physical activity, health impairments, and disability in neuromuscular disease[J]. Am J Phys Med Rehabil, 2002, 81(11 Suppl): S108-S120.
[4] McDonald CM, Widman LM, Walsh DD, et al. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy[J]. Arch Phys Med Rehabil, 2005, 86(4): 802-808.
[5] Bushby K, Finkel R, Birnkrant DJ, et al.Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management[J]. Lancet Neurol, 2010, 9(1): 77-93.
[6] Eagle M, Baudouin SV, Chandler C, et al.Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation[J]. Neuromuscul Disord, 2002, 12(10): 926-929.
[7] Mazzone E, Martinelli D, Berardinelli A, et al.North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2010, 20(11): 712-716.
[8] McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study[J]. Muscle Nerve, 2013, 48(3): 343-356.
[9] Escorcio R, Caromano FA, Hukuda ME, et al.Development of an evaluation scale for sitting and standing from the ground for children with Duchenne muscular dystrophy[J]. J Mot Behav, 2011, 43(1): 31-36.
[10] ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test[J]. Am J Respir Crit Care Med, 2002, 166(1): 111-117.
[11] Bushby K, Connor E.Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings[J]. Clin Investig (Lond), 2011, 1(9): 1217-1235.
[12] McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study[J]. Muscle Nerve, 2013, 48(3): 357-368.
[13] McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations[J]. Muscle Nerve, 2010, 42(6): 966-974.
[14] Mazzone E, Vasco G, Sormani MP, et al.Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study[J]. Neurology, 2011, 77(3): 250-256.
[15] Henricson E, Abresch R, Han JJ, et al. Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences [J]. PLoS Curr, 2012, 4: RRN1297.
[16] Goemans N, Van Den Hauwe M, Wilson R, et al. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids[J]. Neuromuscul Disord, 2013, 23(8): 618-623.
[17] Scott OM, Hyde SA, Goddard C, et al.Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy[J]. Muscle Nerve, 1982, 5(4): 291-301.
[18] Wyrwich KW, Nienaber NA, Tierney WM, et al.Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life[J]. Med Care, 1999, 37(5): 469-478.
[19] Hyde SA, Steffensen BF, Fløytrup I, et al.Longitudinal data analysis: an application to construction of a natural history profile of Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2001, 11(2): 165-170.
[20] Beenakker EA, Maurits NM, Fock JM, et al.Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients[J]. Eur J Paediatr Neurol, 2005, 9(6): 387-393.
[21] Vignos PJ, Spencer GE, Archibald KC.Management of progressive muscular dystrophy in childhood[J]. JAMA, 1963, 184: 89-96.
[22] Mazzone ES, Coratti G, Sormani MP, et al.Timed rise from floor as a predictor of disease progression in duchenne muscular Dystrophy: an observational study[J]. PLoS One, 2016, 11(3): e0151445.
[23] Bendixen RM, Lott DJ, Senesac C, et al.Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy[J]. Disabil Rehabil, 2014, 36(22): 1918-1923.
[24] Martini J, Hukuda ME, Caromano FA, et al.The clinical relevance of timed motor performance in children with Duchenne muscular dystrophy[J]. Physiother Theory Pract, 2015, 31(3): 173-181.
[25] Fernandes LA, Caromano FA, Assis SM, et al.Relationship between the climbing up and climbing down stairs domain scores on the FES-DMD, the score on the Vignos Scale, age and timed performance of functional activities in boys with Duchenne muscular dystrophy[J]. Braz J Phys Ther, 2014, 18(6): 513-520.
Outlines

/

〈 〉